Insider Cluster (2 insiders) ·Filed Apr 17, 2026

KALV

KalVista Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $231K total
Actionable Insight ▼ Bearish

C-suite selling totaling $231K represents modest but notable insider divestment (~0.023% of $1.0B market cap). Monitor next earnings report for potential downward revisions or lack of catalysts that could explain profit-taking. Non-cash derivative exercises are routine, but open-market sales by CEO and CFO raise caution.

DirectionBearish
Confidencehigh
Horizondays
Latest settled — T+20d
KALV ▲ +30.66% at T+20d
SHORT call ✗ call lost -30.66% · α vs SPY -25.29% · entry $20.48 → $26.76
Next anchor: T+60d due 3mo ago
Latest observation: T+39 -4.90% FF3 residual α
Entry anchored
Apr 16, 03:59 PM ET
via exchange tick
T+1d
+1.90%
call -1.90% · α -2.10%
$20.87
settled 6mo ago
T+5d
-4.15%
call +4.15% · α +4.71%
$19.63
settled 5mo ago
T+20d
+30.66%
call -30.66% · α -25.29%
$26.76
settled 5mo ago
T+60d
—
call — · α —
—
due 3mo ago

Price Chart

Loading chart...

Executive Summary

KalVista Pharmaceuticals executives Palleiko (CEO) and Piekos (CFO) sold shares worth $231K in aggregate over a 7-day window, including open-market sales totaling $231K. The transactions follow derivative exercises, which are non-cash events.

Key Financial Metrics

Direction
selling
Total Value
$231.0K
Insiders
2

Key Facts

  • CEO Palleiko sold $193K of stock in open-market transactions on 2026-04-17.
  • CFO Piekos sold $38K of stock in open-market transactions on 2026-04-17.
  • Both executives also exercised derivatives (totaling $0 value) on 2026-04-16, which are routine non-cash events.
  • Total open-market selling by insiders: $231K over 7 days.

Financial Impact

$231,000 in open-market selling by C-suite executives

insider ownershipmarket sentiment

Risk Factors

  • Insider selling may signal lack of confidence in near-term prospects
  • Potential for negative market perception despite modest dollar size

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KALV-1776728476891
12 reports for KALV
Performance horizon
40% Hit rate 2 of 5 directional calls best @ T+20▲ +0.45%Apr 29, 2026
Filters
Rows
Reports for KALV — sortable, filterable
TypeNow
Jun 22, 2026
14w ago
15-12G
BEARISH ★ 7/10
—awaiting T+1——
Jun 17, 2026
15w ago
EFFECT
NEUTRAL ★ 3/10
$27.00 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
8-K
NEUTRAL ★ 5/10
$26.99 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 2/10
$27.00 $27.00· 0.00%▼ −0.54%—
May 19, 2026
19w ago
Insider Cluster
BEARISH ★ 5/10
$26.81 $26.77▲ +0.15%▲ +0.34%—
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.81 $26.77▼ −0.15%▼ −0.34%—
Apr 29, 2026
22w ago
8-K
BULLISH ★ 8/10
$26.67 $26.66▼ −0.04%▼ −1.06%—
Apr 17, 2026
24w ago
Insider Cluster
BEARISH ★ 6/10
$20.48 $20.87▼ −1.90%▼ −2.10%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 7/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Showing 10 of 12

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 20, 2026